TRAWS PHARMA(TRAW),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

TRAW TRAWS PHARMA

Post-Mkt 12-22 17:37:41 EST

1.32

+0.05

+3.53%

盘后1.34

+0.02+1.44%

17:03 EST

High1.34	Low1.20	Vol167.98K
Open1.29	D1 Closing1.28	Amplitude10.98%
Mkt Cap10.55M	Tradable Cap7.82M	Total Shares7.99M
T/O217.49K	T/O Rate2.83%	Tradable Shares5.93M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"TRAW","market":"US","secType":"STK","nameCN":"TRAWS PHARMA","latestPrice":1.32,"timestamp":1766437200000,"preClose":1.275,"halted":0,"volume":167975,"hourTrading":{"tag":"盘后","latestPrice":1.339,"preClose":1.32,"latestTime":"17:03 EST","volume":2283,"amount":3022.2484131,"timestamp":1766441026424},"delay":0,"floatShares":5925700,"shares":7990867,"eps":-1.070813,"marketStatus":"Post-Mkt","change":0.045,"latestTime":"12-22 17:37:41 EST","open":1.29,"high":1.34,"low":1.2,"amount":217491.3424,"amplitude":0.109804,"askPrice":1.35,"askSize":100,"bidPrice":1.24,"bidSize":1,"shortable":3,"etf":0,"ttmEps":-1.070813,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1766451600000},"marketStatusCode":4,"adr":0,"listingDate":1374724800000,"exchange":"NASDAQ","adjPreClose":1.275,"preHourTrading":{"tag":"盘前","latestPrice":1.31,"preClose":1.275,"latestTime":"09:29 EST","volume":3586,"amount":4642.0013354,"timestamp":1766413799129},"postHourTrading":{"tag":"盘后","latestPrice":1.339,"preClose":1.32,"latestTime":"17:03 EST","volume":2283,"amount":3022.2484131,"timestamp":1766441026424},"volumeRatio":0.151956,"impliedVol":1.6331,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/TRAW","defaultTab":"news","newsList":[{"id":"2592399184","title":"Traws Pharma Reports Positive Interim Results for Ratutrelvir in Paxlovid-Ineligible COVID-19 Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2592399184","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592399184?lang=en_us&edition=fundamental","pubTime":"2025-12-17 19:00","pubTimestamp":1765969221,"startTime":"0","endTime":"0","summary":"Traws Pharma Inc. has announced interim data from an ongoing randomized, open-label Phase 2 clinical study of ratutrelvir, an investigational oral, ritonavir-free Mpro/3CL protease inhibitor, in patients with mild-to-moderate COVID-19. The interim analysis demonstrated a differentiated clinical profile for ratutrelvir compared to PAXLOVID, with fewer adverse events and no viral rebounds. The data also indicated activity in patients who are ineligible for Paxlovid, addressing a population with limited treatment options. The final data analysis from the study is expected to be reported in January 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Traws Pharma Inc. published the original content used to generate this news brief via Glob","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDL38GghF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU2210150020.SGD","LU2095319765.USD","BK4007","BK4585","IE00BKPKM429.USD","SG9999014039.USD","SG9999014013.SGD","SG9999014021.USD","TRAW","BK4112","IE00B64PRP62.GBP","IE00BGHQF748.EUR","LU0314104364.USD","LU2210149790.SGD","IE00B3QW5Z07.USD","NDAQ","SG9999014005.SGD"],"gpt_icon":0},{"id":"2592991829","title":"Traws Pharma Inc: Ratutrelvir Shows a Differentiated Profile Versus Paxlovid™ With Fewer Adverse Events and No Viral Rebounds","url":"https://stock-news.laohu8.com/highlight/detail?id=2592991829","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592991829?lang=en_us&edition=fundamental","pubTime":"2025-12-17 19:00","pubTimestamp":1765969201,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nTUA6Q2DH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TRAW"],"gpt_icon":0},{"id":"2592991823","title":"Traws Pharma Inc: Final Data Analysis to Be Reported in January 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2592991823","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592991823?lang=en_us&edition=fundamental","pubTime":"2025-12-17 19:00","pubTimestamp":1765969201,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nTUA6Q2DH:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TRAW"],"gpt_icon":0},{"id":"2592918579","title":"Traws Pharma Reports Positive Interim Clinical Data With Ratutrelvir Versus Paxlovid™, Shows Activity in Paxlovid-Ineligible Covid-19 Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2592918579","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592918579?lang=en_us&edition=fundamental","pubTime":"2025-12-17 19:00","pubTimestamp":1765969201,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nTUA6Q2DH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TRAW","BK4007"],"gpt_icon":0},{"id":"2592958804","title":"Traws Pharma Grants Stock Options and RSUs to Executive Team","url":"https://stock-news.laohu8.com/highlight/detail?id=2592958804","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592958804?lang=en_us&edition=fundamental","pubTime":"2025-12-17 06:01","pubTimestamp":1765922477,"startTime":"0","endTime":"0","summary":"Traws Pharma Inc. has announced new equity compensation awards for its executive officers. On December 12, 2025, the company's Compensation Committee approved the grant of stock options and restricted stock units  under its Amended and Restated 2021 Incentive Compensation Plan. Chief Executive Officer Iain Dukes received 147,771 options and 36,943 RSUs, Chief Financial Officer Charles Parker received 61,571 options and 15,393 RSUs, and Chief Science Officer, Virology, C. David Pauza received 73,886 options and 18,471 RSUs. Chief Medical Officer Robert Redfield and Chief Operating Officer Nikolay Savchuk were each awarded 65,676 options and 16,419 RSUs. The options have an exercise price of $2.33 per share, a ten-year term, and will vest in full on the first anniversary of the grant date, contingent on continued service.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nNDL1wrvY7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TRAW"],"gpt_icon":0},{"id":"2588304501","title":"HC Wainwright Initiates Traws Pharma at Buy With $8 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2588304501","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588304501?lang=en_us&edition=fundamental","pubTime":"2025-12-03 20:39","pubTimestamp":1764765553,"startTime":"0","endTime":"0","summary":"HC Wainwright Initiates Traws Pharma at Buy With $8 Price Target","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","TRAW"],"gpt_icon":0},{"id":"2588045364","title":"Traws Pharma Initiated at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2588045364","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588045364?lang=en_us&edition=fundamental","pubTime":"2025-12-03 20:10","pubTimestamp":1764763800,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TRAW/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 03, 2025 07:10 ET (12:10 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TRAW"],"gpt_icon":0},{"id":"2588101075","title":"Traws Pharma, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2588101075","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588101075?lang=en_us&edition=fundamental","pubTime":"2025-12-03 19:02","pubTimestamp":1764759763,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nAZN4R6ELH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TRAW","BK4007"],"gpt_icon":0},{"id":"2587815730","title":"Traws Pharma Inc. Held Annual Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2587815730","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2587815730?lang=en_us&edition=fundamental","pubTime":"2025-11-29 05:31","pubTimestamp":1764365493,"startTime":"0","endTime":"0","summary":"Traws Pharma Inc. held its annual meeting of stockholders on November 21, 2025. At the meeting, all nominated directors were elected to the board. Stockholders also approved an amendment and restatement of the company's incentive compensation plan, which increases the number of shares reserved for issuance and extends the plan's term.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Traws Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 28, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251128:nNDL6c27Q5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRAW","BK4007"],"gpt_icon":0},{"id":"2583456223","title":"Traws Pharma Q3 EPS $(0.34) Up From $(8.81) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2583456223","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583456223?lang=en_us&edition=fundamental","pubTime":"2025-11-13 20:17","pubTimestamp":1763036250,"startTime":"0","endTime":"0","summary":"Traws Pharma Q3 EPS $(0.34) Up From $(8.81) YoY","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48830377/traws-pharma-q3-eps-0-34-up-from-8-81-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TRAW"],"gpt_icon":0},{"id":"2583562862","title":"Traws Pharma posts $4.0 million net loss on zero revenue for Q3 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2583562862","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583562862?lang=en_us&edition=fundamental","pubTime":"2025-11-13 20:03","pubTimestamp":1763035425,"startTime":"0","endTime":"0","summary":"Traws Pharma Inc. reported a net loss of $4.0 million, or $0.34 per basic and diluted common share, for the quarter ended September 30, 2025, compared to a net loss of $8.5 million, or $1.49 per share, for the same period in 2024. Revenue for the quarter was zero, down from $57,000 in the prior year period. Research and development expenses totaled $2.3 million, down from $5.1 million, while general and administrative expenses were $1.7 million, compared to $3.5 million in the third quarter of 2024. The company had 8.0 million shares of common stock outstanding as of November 10, 2025. During the period, Traws Pharma acquired intellectual property and other assets associated with a pyrrolidine antiviral compound from Viriom, Inc. for $2.6 million and continued Phase 2 studies for ratutrelvir, an investigational oral protease inhibitor for acute and long COVID, with top-line data expected by year end.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL7QVp4d:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","TRAW"],"gpt_icon":0},{"id":"2583562440","title":"Traws Pharma Inc: Q3 EPS $-0.34","url":"https://stock-news.laohu8.com/highlight/detail?id=2583562440","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583562440?lang=en_us&edition=fundamental","pubTime":"2025-11-13 20:00","pubTimestamp":1763035206,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nTUA2XBV93:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TRAW"],"gpt_icon":0},{"id":"2583556471","title":"Press Release: Traws Pharma Reports Third Quarter 2025 Results and Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2583556471","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583556471?lang=en_us&edition=fundamental","pubTime":"2025-11-13 20:00","pubTimestamp":1763035200,"startTime":"0","endTime":"0","summary":"Progressing Phase 2 studies for ratutrelvir, a ritonavir-free, protease inhibitor regimen in development for Acute and Long COVID with expected top line data by year end. NEWTOWN, Pa., Nov. 13, 2025  -- Traws Pharma, Inc.  , a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today reported financial results for the quarter ended September 30, 2025 and provided recent business highlights for its antiviral programs.Ratutrelvir : Potential best-in-class therapy to minimize the risk of viral rebound and Long COVID. A ritonavir-independent investigational oral Main protease  inhibitor designed to be administered as a single dose, with potential for once-daily, 10-day dosing. -- Intended Indication: Treatment of acute COVID infection, with potential. to reduce the risk of COVID rebound and Long COVID, including in. -- U.S. Market Opportunity: Estimated to be a multi-billion dollar. study to evaluat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4218","BK4007","R","BK4022","BK4181","TRAW","PK","BK4232"],"gpt_icon":0},{"id":"2579124992","title":"Traws Pharma Extends CMC Services Contract With ChemDiv for Ratutrelvir Clinical Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2579124992","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579124992?lang=en_us&edition=fundamental","pubTime":"2025-10-31 00:00","pubTimestamp":1761840030,"startTime":"0","endTime":"0","summary":"Traws Pharma Inc. has extended its collaboration with ChemDiv for Chemistry, Manufacturing and Controls  services to support the clinical development of ratutrelvir, an oral antiviral treatment for COVID-19 currently in Phase 2 clinical trials. The updated agreement includes CMC process research and scale-up for manufacturing, medicinal chemistry support, translational pharmacology services, and clinical pharmacology consulting. Additionally, Expert Systems has extended its contract with Traws Pharma to provide predictive safety pharmacology services using its AI-enabled platform to support further clinical development of ratutrelvir.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Traws Pharma Inc. published the original content used t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nNDL8lBVYp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B7SZL793.SGD","IE00B66KJ199.SGD","BK4127","BK4007","RILY","IE0031619046.USD","TRAW","IE00B19Z4B17.USD"],"gpt_icon":0},{"id":"2579124542","title":"Chemdiv Extends Cmc Services Collaboration for Ratutrelvir, a Potential Best-in-Class Covid-19 Therapeutic Advancing in Phase 2 Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2579124542","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579124542?lang=en_us&edition=fundamental","pubTime":"2025-10-31 00:00","pubTimestamp":1761840000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nTUABCT4KW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TRAW","BK4007"],"gpt_icon":0},{"id":"2577341348","title":"Traws Pharma Launches Phase 2 Trial of Ritonavir-Free COVID-19 Antiviral Ratutrelvir","url":"https://stock-news.laohu8.com/highlight/detail?id=2577341348","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577341348?lang=en_us&edition=fundamental","pubTime":"2025-10-23 06:40","pubTimestamp":1761172846,"startTime":"0","endTime":"0","summary":"Traws Pharma Inc. has announced the initiation of Phase 2 clinical studies for Ratutrelvir , a novel oral antiviral developed for newly diagnosed COVID-19 patients. Ratutrelvir is designed as a ritonavir-free treatment and aims to address the needs of populations who are ineligible for current standard-of-care antiviral options, such as PAXLOVID. The drug has shown broad-spectrum in vitro activity against multiple SARS-CoV-2 strains and maintains high potency without the need for ritonavir co-administration, potentially reducing drug-drug interactions. In Phase 1 multiple ascending dose studies, the daily oral regimen demonstrated sustained plasma concentrations above key efficacy thresholds for a 10-day course and was reported to have an excellent safety profile. The results of the Phase 2 clinical study have not yet been presented and will be announced in the future.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT st","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251022:nNDL5xTkK8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRAW","BK4007"],"gpt_icon":0},{"id":"2576064376","title":"Traws Pharma Grants Stock Options to Executive Team","url":"https://stock-news.laohu8.com/highlight/detail?id=2576064376","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576064376?lang=en_us&edition=fundamental","pubTime":"2025-10-18 05:04","pubTimestamp":1760735069,"startTime":"0","endTime":"0","summary":"Traws Pharma Inc. has approved new stock option grants for its executive officers. On October 12, 2025, the company's Compensation Committee granted options to purchase shares of common stock at an exercise price of $3.01 per share. The grants include 64,839 options to Chief Executive Officer Iain Dukes, 32,406 options each to Chief Financial Officer Charles Parker, Chief Science Officer, Virology C. David Pauza, and Chief Medical Officer Robert Redfield, and 22,435 options to Chief Operating Officer Nikolay Savchuk. The options have a ten-year term and will vest in full on the first anniversary of the grant date, provided the recipients remain with the company. These options were issued under Traws Pharma's Amended and Restated 2021 Incentive Compensation Plan.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251017:nNDL4l28KX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRAW","BK4007"],"gpt_icon":0},{"id":"2575257182","title":"Traws Pharma Inc. Files Initial Beneficial Ownership Statement for Director John Harold Leaman","url":"https://stock-news.laohu8.com/highlight/detail?id=2575257182","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575257182?lang=en_us&edition=fundamental","pubTime":"2025-10-15 07:01","pubTimestamp":1760482906,"startTime":"0","endTime":"0","summary":"Traws Pharma Inc. has filed an initial statement of beneficial ownership  with the U.S. Securities and Exchange Commission. The filing names John Harold Leaman as a Director of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Traws Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 14, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nNDL83Jl9X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRAW","BK4007"],"gpt_icon":0},{"id":"2575291499","title":"Traws Pharma Begins Phase 2 Trials of Ritonavir-Free COVID Treatment Ratutrelvir, Results Expected by Year-End 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2575291499","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575291499?lang=en_us&edition=fundamental","pubTime":"2025-10-14 19:02","pubTimestamp":1760439744,"startTime":"0","endTime":"0","summary":"Traws Pharma Inc. has announced the initiation of two Phase 2 clinical studies evaluating ratutrelvir, a ritonavir-free antiviral treatment for COVID-19. The first study is a non-inferiority trial comparing ratutrelvir to PAXLOVID, assessing safety, efficacy, rates of disease rebound, and incidence of Long COVID. The second is a single-arm trial evaluating safety and efficacy in patients who are ineligible for PAXLOVID, a group considered at higher risk for poor outcomes and with limited treatment options. Top-line data from both trials are expected by year-end 2025. No study results have been presented yet.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Traws Pharma Inc. published the original content used to generate this news brief ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nNDLWl1Sz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRAW","BK4007"],"gpt_icon":0},{"id":"2575993291","title":"Traws Pharma Inc -Top-Line Data From Both Trials Expected by Year-End 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2575993291","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575993291?lang=en_us&edition=fundamental","pubTime":"2025-10-14 19:00","pubTimestamp":1760439602,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251014:nTUA2KGX8F:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","TRAW"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.onconova.com","stockEarnings":[{"period":"1week","weight":-0.4528},{"period":"1month","weight":-0.3957},{"period":"3month","weight":-0.3719},{"period":"6month","weight":-0.2365},{"period":"1year","weight":-0.761},{"period":"ytd","weight":-0.8564}],"compareEarnings":[{"period":"1week","weight":-0.0017},{"period":"1month","weight":0.0271},{"period":"3month","weight":0.0254},{"period":"6month","weight":0.1452},{"period":"1year","weight":0.1612},{"period":"ytd","weight":0.1613}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.122614},{"month":2,"riseRate":0.416667,"avgChangeRate":-0.076386},{"month":3,"riseRate":0.416667,"avgChangeRate":-0.052994},{"month":4,"riseRate":0.25,"avgChangeRate":-0.132766},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.059914},{"month":6,"riseRate":0.75,"avgChangeRate":0.06745},{"month":7,"riseRate":0.25,"avgChangeRate":-0.019463},{"month":8,"riseRate":0.230769,"avgChangeRate":-0.120142},{"month":9,"riseRate":0.384615,"avgChangeRate":-0.103896},{"month":10,"riseRate":0.230769,"avgChangeRate":-0.080722},{"month":11,"riseRate":0.461538,"avgChangeRate":-0.058331},{"month":12,"riseRate":0.307692,"avgChangeRate":0.013708}],"exchange":"NASDAQ","name":"TRAWS PHARMA","nameEN":"TRAWS PHARMA"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"TRAWS PHARMA(TRAW),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest TRAWS PHARMA(TRAW) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"TRAWS PHARMA,TRAW,TRAWS PHARMA股票,TRAWS PHARMA股票老虎,TRAWS PHARMA股票老虎国际,TRAWS PHARMA行情,TRAWS PHARMA股票行情,TRAWS PHARMA股价,TRAWS PHARMA股市,TRAWS PHARMA股票价格,TRAWS PHARMA股票交易,TRAWS PHARMA股票购买,TRAWS PHARMA股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"TRAWS PHARMA(TRAW),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest TRAWS PHARMA(TRAW) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}